-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Zentek Provides Update on Rumours
Zentek Provides Update on Rumours
GUELPH, ON / ACCESSWIRE / March 8, 2022 / Zentek Ltd. ("ZEN" or the "Company") (TSXV:ZEN)(OTC PINK:ZENYF), a Canadian IP development and commercialization company focused on next-gen healthcare solutions has become aware of certain rumours and allegations being circulated, and categorically refutes the egregious allegation regarding the theft of intellectual property from Graphene Composites Ltd.
On January 29, 2021, the Company was served with a statement claim issued by Graphene Composites Ltd. and is in the process of defending the action, which it considers frivolous and without merit. The Company has considered the allegations as set out in the claim and, in light of the facts, the lack of clarity in the claim, and, based on discussions with the Company's litigation counsel, the assessment of the merits of the claim and the defenses available to the Company, and the Company's conclusion is that the risk of the Company suffering loss in respect of the claim is remote, and therefore the Company determined the claim not to be material or constituting "significant litigation" pursuant to the policies of the TSX Venture Exchange. The Company continues to view this claim as frivolous and will continue to vigorously defend itself against these allegations.
The Company is aware of a 2,904,839 share Consolidated Short Position (less than 3% of total shares outstanding) in the marketplace as of March 1, 2022. Furthermore, the Company believes these false allegations were meant to hurt the Company's credibility.
About Zentek Ltd.
Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is commercializing ZenGUARD™, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases. The Company also has an exclusive agreement to be the global exclusive commercializing partner for a newly developed, highly scalable, aptamer-based rapid pathogen detection technology.
For further information:
Matt Blazei
Tel: (212) 655-0924
Email: mattb@coreir.com
To find out more about Zentek Ltd., please visit our website at . A copy of this news release and all material documents in respect of the Company may be obtained on ZEN's SEDAR profile at .
Forward-Looking Statements
This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Zentek Ltd.
View source version on accesswire.com:
GUELPH, ON / ACCESSWIRE / March 8, 2022 / Zentek Ltd. ("ZEN" or the "Company") (TSXV:ZEN)(OTC PINK:ZENYF), a Canadian IP development and commercialization company focused on next-gen healthcare solutions has become aware of certain rumours and allegations being circulated, and categorically refutes the egregious allegation regarding the theft of intellectual property from Graphene Composites Ltd.
Guelph,on/ACCESSWIRE/2022年3月8日/Zentek Ltd. ("禅宗“或”公司)(多伦多证券交易所股票代码:ZEN)(场外交易代码:ZENYF),一家专注于下一代医疗解决方案的加拿大知识产权开发和商业化公司已经意识到正在流传的某些谣言和指控,并断然驳斥了有关窃取石墨烯复合材料有限公司知识产权的骇人听闻的指控。
On January 29, 2021, the Company was served with a statement claim issued by Graphene Composites Ltd. and is in the process of defending the action, which it considers frivolous and without merit. The Company has considered the allegations as set out in the claim and, in light of the facts, the lack of clarity in the claim, and, based on discussions with the Company's litigation counsel, the assessment of the merits of the claim and the defenses available to the Company, and the Company's conclusion is that the risk of the Company suffering loss in respect of the claim is remote, and therefore the Company determined the claim not to be material or constituting "significant litigation" pursuant to the policies of the TSX Venture Exchange. The Company continues to view this claim as frivolous and will continue to vigorously defend itself against these allegations.
2021年1月29日,该公司收到了石墨烯复合材料有限公司发布的一份声明索赔,并正在为这一诉讼辩护,该公司认为这是轻率和没有道理的。本公司已考虑申索中所载的指控,并根据申索不清晰的事实,并根据与本公司诉讼律师的讨论,评估申索的是非曲直及本公司可提出的抗辩理由,而本公司的结论是,本公司就申索蒙受损失的风险微乎其微,因此,根据多伦多证券交易所创业板的政策,本公司裁定该申索并非重大或构成“重大诉讼”。该公司继续认为这一指控是轻率的,并将继续针对这些指控积极为自己辩护。
The Company is aware of a 2,904,839 share Consolidated Short Position (less than 3% of total shares outstanding) in the marketplace as of March 1, 2022. Furthermore, the Company believes these false allegations were meant to hurt the Company's credibility.
该公司知道,截至2022年3月1日,市场上有2,904,839股综合空头头寸(不到总流通股的3%)。此外,本公司认为这些虚假指控意在损害本公司的信誉。
About Zentek Ltd.
关于Zentek有限公司
Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is commercializing ZenGUARD™, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases. The Company also has an exclusive agreement to be the global exclusive commercializing partner for a newly developed, highly scalable, aptamer-based rapid pathogen detection technology.
Zentek是一家知识产权开发和商业化公司,专注于预防、检测和治疗领域的下一代医疗解决方案。Zentek正在将禅宗商业化警卫™是一种正在申请专利的涂料,具有99%的抗菌活性,包括对新冠肺炎的抗菌活性,并有可能将类似化合物用作治疗传染病的药品。该公司还签订了一项独家协议,将成为一项新开发的、高度可扩展的、基于适体的快速病原体检测技术的全球独家商业化合作伙伴。
For further information:
有关更多信息,请访问:
Matt Blazei
Tel: (212) 655-0924
Email: mattb@coreir.com
马特·布拉泽(Matt Blazei)
电话:(212)655-0924
电子邮件:mattb@coreir.com
To find out more about Zentek Ltd., please visit our website at . A copy of this news release and all material documents in respect of the Company may be obtained on ZEN's SEDAR profile at .
欲了解更多有关Zentek Ltd.的信息,请访问我们的网站:。本新闻稿的副本和与本公司有关的所有重要文件可在Zen的SEDAR简介中获得,网址为。
Forward-Looking Statements
前瞻性陈述
This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
本新闻稿包含前瞻性陈述。由于前瞻性陈述涉及未来的事件和条件,因此它们本身就包含固有的风险和不确定因素。尽管Zentek认为在准备本新闻稿中的前瞻性信息时使用的假设和因素是合理的,但不应过度依赖这些信息,因为这些信息只适用于本新闻稿发布之日,不能保证此类事件将在披露的时间框架内发生或根本不会发生。除法律要求外,Zentek没有任何更新或修改任何前瞻性信息的意图或义务,无论是由于新信息、未来事件还是其他原因。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多伦多证券交易所创业板交易所及其监管服务提供商(该术语在多伦多证券交易所创业板政策中定义)均不对本新闻稿的充分性或准确性承担责任。
SOURCE: Zentek Ltd.
资料来源:Zentek Ltd.
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧